STAT+: What to know about the polarizing ALS drug headed for FDA scrutiny next week
Years of polarizing scientific discourse and bruising online debate will come to a head next…
Author: STAT
Opinion: Brain drain, skills loss, and other unintended consequences of overturning Roe v. Wade
Every day at the Kansas clinic where I perform abortions, I take care of pregnant…
STAT+: Approval setback for EpiPen alternative puts spotlight on common anti-competition tactic
Americans who suffer severe allergic reactions won’t have alternatives to autoinjectors like the Epipen for…
STAT+: Hearing on Medicare drug price negotiation gets unusually heated
WASHINGTON — Republicans and Democrats fought it out over Medicare drug price negotiation Wednesday at…
Weed smokers often can’t work for the government. Some Republicans want to keep it that way
WASHINGTON — Roughly three quarters of states have legalized marijuana either for medical or recreational…
STAT+: Novartis is scolded by U.K. trade group for the fourth time this year over Entresto promotions
For the fourth time this year, Novartis has been reprimanded by a U.K. trade group…
Free Covid tests will be offered again to all U.S. households
The federal government is again offering free Covid-19 tests to Americans, providing a fifth round…
STAT+: Northeastern among sites chosen by CDC to establish ‘National Weather Service’ for infectious disease
Northeastern University has been selected for a leading role in a new national network formed…
STAT+: A breakthrough cystic fibrosis drug gave them the gift of time. But miracles come with complications.
The small box full of promises arrived at Jessica Anderson’s home on her 31st birthday….
Researchers use AI to measure recovery from treatment-resistant depression
Researchers say they’ve been able to measure recovery from treatment-resistant depression through brain scans —…
STAT Virtual Event: Putting AI to the Test
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
FDA asks for more data before considering needle-free anaphylaxis treatment
ARS Pharma had high hopes that the FDA on Tuesday would approve its flagship product,…
STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro
As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding…
Opinion: Value-based payments are making it harder to see your primary care doctor on short notice
Difficulty scheduling an urgent or time-sensitive appointment is now the most common gripe my patients…
Does the risk of getting long Covid increase each time you get reinfected?
More than three years into the coronavirus pandemic, fewer and fewer people are experiencing their…
STAT+: AI is coming to your dentist’s office. Will it build trust, or erode it?
Open wide, AI wants a look inside your mouth. A new wave of software is…
STAT+: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind
Apellis Pharmaceuticals has been slowly rebounding from an unjustified safety scare related to its approved…
STAT+: How a cash-prize system that phases out patents may lower drug prices
Two months ago, Sen. Bernie Sanders (I-Vt.) moved a step closer to an idea he…
STAT+: FDA weighs animal data, ethical dilemmas at panel on artificial wombs
The Food and Drug Administration’s advisory panel of pediatric experts met on Tuesday to discuss…
STAT+: PBMs were the target of House hearing, but pharma wasn’t spared criticism
WASHINGTON — Congress wants to reform PBM business practices to help lower the cost of…
.jpg)
STAT+: Pear’s shadow effect: Data from a Medicaid digital health experiment does the policy rounds
Pear Therapeutics may be gone, but one of its most important deals is still driving…
STAT+: What happened to the House vote on health care price transparency?
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter in your…
STAT+: Biotech lab-space demand falls sharply as industry’s ‘sugar high’ turns into a ‘reset’
Demand for new lab space has plummeted by more than half since the end of…
STAT+: Pharmalittle: Cepheid agrees to sell a TB test at cost; Mallinckrodt weighs selling some or all businesses
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: After a high-profile pressure campaign, Cepheid agrees to sell a TB test at cost
Following a high-profile pressure campaign, the company that makes a crucial tuberculosis test has agreed…
STAT+: Artificial wombs, after years in development, reach FDA review for human trials
The artificial womb, a device aiming to save infants born way too soon, is inching…
Physicians say transgender sports bans are a health issue
Almost half of U.S. states have banned or restricted trans youths’ access to gender-affirming puberty…
Rep. Adam Smith weighs in on the country’s mental health crisis with his own story
WASHINGTON — Rep. Adam Smith (D-Wash.) knew when he hit rock bottom. “I woke up…
Opinion: A popular breast cancer genomic test underestimates risks for Black women
When a woman first learns she has breast cancer, her mind immediately floods with “what…
STAT+: Patients, doctors press FTC to beef up hospital merger scrutiny
Comments to antitrust regulators lay bare Americans’ anger and disillusionment over consolidation’s effects on all…
STAT+: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Opinion: Where are HHS and the FTC on online privacy for people with substance use disorder?
The era of rampant, unconsented, and unregulated online data collection may finally be winding down…
STAT+: Medicare wants to increase payments for heart rehab. Hospitals see an opening to get more
Medicare plans to pay more for a type of cardiac rehabilitation that takes place in…
Why doesn’t the U.S. have more Black midwives?
In the wake of growing alarm over the disproportionately high rates of maternal mortality in…
STAT+: David Liu startup to focus on getting CRISPR therapy to hard-to-reach cells
David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching…
STAT+: South Africa investigates Johnson & Johnson over ‘excessive pricing’ for its TB drug
South African authorities are investigating Johnson & Johnson and its Janssen subsidiary over “excessive pricing”…
STAT+: Chamber of Commerce, government clash at first court hearing on Medicare drug prices
WASHINGTON — Attorneys for the U.S. Chamber of Commerce and the federal government sparred Friday…
STAT+: Dana-Farber deal highlights a surprising trend: New cancer centers are in vogue
Boston isn’t the only city slated for a new cancer center. Far from it. There’s…
STAT+: Dana-Farber blindsided Brigham and Women’s. The blowback will be strong
This column is from Trendlines, a business newsletter that covers the forces shaping the economy…
STAT+: Pharmalittle: House panel inches into fixing drug shortages; pharma could face legal action over improper patent listings
And so, another working week will soon draw to a close. Not a moment too…
Opinion: The morally ground-shifting legacy of Ian Wilmut and Dolly the sheep
Ian Wilmut, the British scientist behind the first-ever cloning of a mammal, died Sept. 10,…
Opinion: How the Wegovy shortage is making life impossible for my patients — and for me
There is just not enough Wegovy. The current manufacturing shortage will eventually end, and those…
Polio transmission was supposed to end by 2023. A new report explains why it won’t.
The latest goal for the end of polio transmission will almost certainly not be met,…
Randomized controlled trials are the ‘gold standard’ of research — but a difficult fit for trans care
In order to provide gender-affirming care, clinicians must sometimes jump through unusual hoops. In Australia,…
Johnson & Johnson is getting rid of its script logo after more than 130 years
Johnson & Johnson is signing off on a new logo. The health care giant said…
Listen: Covid’s latest surge, Alnylam at the FDA, & the end of an era
What does Covid-19 have in store for the winter? When are good data not good…
STAT+: House subcommittee forays into fixing drug shortages
WASHINGTON — A House subcommittee took a first step today toward legislation to fix drug…
STAT+: FTC warns drugmakers they can face legal action over improper patent filings
The Federal Trade Commission warned pharmaceutical companies they could face legal action if they improperly…
STAT+: Dana-Farber, in break with Brigham and Women’s, will build new cancer center with Beth Israel
Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center have announced plans to build a…